Insider Selling: Agios Pharmaceuticals Inc (AGIO) Insider Sells $209,070.00 in Stock
Agios Pharmaceuticals Inc (NASDAQ:AGIO) insider Scott Biller sold 3,000 shares of Agios Pharmaceuticals stock in a transaction that occurred on Monday, November 5th. The stock was sold at an average price of $69.69, for a total value of $209,070.00. Following the sale, the insider now directly owns 53,932 shares of the company’s stock, valued at $3,758,521.08. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.
Scott Biller also recently made the following trade(s):
- On Friday, October 5th, Scott Biller sold 3,000 shares of Agios Pharmaceuticals stock. The stock was sold at an average price of $69.79, for a total value of $209,370.00.
- On Wednesday, September 5th, Scott Biller sold 3,000 shares of Agios Pharmaceuticals stock. The stock was sold at an average price of $83.07, for a total value of $249,210.00.
Shares of NASDAQ AGIO opened at $69.09 on Friday. The firm has a market capitalization of $4.23 billion, a price-to-earnings ratio of -10.24 and a beta of 2.04. Agios Pharmaceuticals Inc has a fifty-two week low of $51.62 and a fifty-two week high of $99.82.
A number of hedge funds and other institutional investors have recently made changes to their positions in AGIO. Rockefeller Capital Management L.P. acquired a new position in Agios Pharmaceuticals in the 3rd quarter valued at $134,000. Tiverton Asset Management LLC bought a new position in shares of Agios Pharmaceuticals in the 2nd quarter valued at $142,000. Strs Ohio bought a new position in shares of Agios Pharmaceuticals in the 2nd quarter valued at $179,000. NewSquare Capital LLC bought a new position in shares of Agios Pharmaceuticals in the 2nd quarter valued at $182,000. Finally, Barrett Asset Management LLC bought a new position in shares of Agios Pharmaceuticals in the 2nd quarter valued at $253,000. 94.38% of the stock is owned by hedge funds and other institutional investors.
Several research firms recently weighed in on AGIO. Piper Jaffray Companies set a $125.00 price target on Agios Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, August 2nd. ValuEngine cut Agios Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Tuesday, September 11th. Needham & Company LLC reissued a “buy” rating on shares of Agios Pharmaceuticals in a report on Thursday, August 2nd. BidaskClub raised Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, September 27th. Finally, Guggenheim started coverage on Agios Pharmaceuticals in a report on Monday, September 17th. They issued a “neutral” rating for the company. Five investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Agios Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $96.27.
ILLEGAL ACTIVITY NOTICE: “Insider Selling: Agios Pharmaceuticals Inc (AGIO) Insider Sells $209,070.00 in Stock” was originally reported by Daily Political and is the sole property of of Daily Political. If you are reading this story on another website, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this story can be read at https://www.dailypolitical.com/2018/11/10/insider-selling-agios-pharmaceuticals-inc-agio-insider-sells-209070-00-in-stock.html.
About Agios Pharmaceuticals
Agios Pharmaceuticals, Inc, a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. It is developing IDHIFA, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase I/II clinical trials for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase III clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase Ib frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase I/II frontline combination trial for patients with newly diagnosed AML.
Further Reading: Understanding Market Liquidity
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.